Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)

NCT05413369 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05413369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
July 7, 2022
Completion date
October 20, 2023
Enrollment
582 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus